HIV-1 Trans-activator of transcription protein (Tat) (Tat)

HIV-1 Trans-activator of transcription protein (Tat) is a crucial regulatory factor (typically 86–101 amino acids) encoded by the HIV-1 genome that is absolutely required for productive viral replication [6][15]. Its primary intracellular function is to serve as a transactivator that binds to the Trans-Activation Response (TAR) RNA element at the 5' end of nascent viral transcripts, subsequently recruiting the host’s positive transcription elongation factor b (P-TEFb) complex [2][3]. This recruitment allows the CDK9 subunit of P-TEFb to phosphorylate the C-terminal domain of RNA Polymerase II, thereby overcoming transcriptional pausing and dramatically increasing the production of full-length viral mRNAs [5][12]. Beyond its transcriptional role, Tat is actively secreted from infected cells and can be internalized by uninfected bystander cells, where it acts as a potent toxin [14][16]. This extracellular activity contributes significantly to the pathogenesis of HIV-associated neurocognitive disorders (HAND), cardiovascular impairment, and the promotion of AIDS-related malignancies such as Kaposi’s sarcoma [8][15][17]. Consequently, Tat is a high-priority target for therapeutic intervention, with strategies ranging from 'block and lock' small-molecule inhibitors like didehydro-cortistatin A (dCA) to therapeutic vaccines designed to elicit neutralizing antibodies [4][18]. Targeting Tat is considered essential for achieving a functional cure by maintaining deep viral latency and reducing the chronic inflammation observed in patients even during antiretroviral therapy [7][11].

Other names

Trans-activator of transcriptionp14p16Transactivating regulatory proteinHIV-1 Tat

Drugs targeting Tat primarily function by inhibiting its binding to the Trans-Activation Response (TAR) RNA element, blocking the recruitment of the Positive Transcription Elongation Factor b (P-TEFb) complex, or eliciting neutralizing antibodies through vaccination to counteract both intracellular and extracellular Tat activities [4][8][18]. These approaches aim to suppress viral transcription elongation and prevent Tat-mediated bystander toxicity [14][16].